Table 2.
Baseline Clinical Characteristics of Study Participants (n = 171)
| Characteristics | Cases, n (%) | Controls, n (%) | X2 | P-value |
|---|---|---|---|---|
| Previous TB history | 13.790 | <0.001 | ||
| Yes | 12 (21.1) | 4 (3.5) | ||
| No | 45 (78.9) | 110 (96.5) | ||
| Baseline functional status | 9.120 | 0.010 | ||
| Working | 43 (75.4) | 105 (92.1) | ||
| Ambulatory | 12 (21.1) | 8 (7.0) | ||
| Bedridden | 2 (3.5) | 1 (0.9) | ||
| Baseline WHO stage | 10.083 | 0.001 | ||
| I/II | 48 (84.2 | 111 (97.4) | ||
| III/ IV | 9 (15.8) | 3 (2.6) | ||
| Baseline Hgb | 6.985 | 0.008 | ||
| <10g/dl | 11 (19.3) | 7 (6.1) | ||
| >10g/dl | 46 (80.7) | 107 (93.9) | ||
| BMI | 3.873 | 0.049 | ||
| <18.5 | 24 (42.1) | 31 (27.2) | ||
| >18.5 | 33 (57.9) | 83 (72.8) | ||
| Initial treatment | 4.309 | 0.230 | ||
| TDF/3TC/NVP | 8 (14.0) | 17 (14.9) | ||
| AZT/3TC/NVP | 0 (0.0) | 5 (4.4.) | ||
| AZT/3TC/EFV | 45 (78.9) | 89 (78.1) | ||
| TDF/3TC/EFV | 4 (7.0) | 3 (2.6) | ||
| Took IPT Prophylaxis | 8.047 | 0.005 | ||
| Yes | 9 (15.8) | 42 (36.8) | ||
| No | 48 (84.2) | 72 (63.2 | ||
| Co-infection | 0.299 | 0.585 | ||
| Yes | 26 (45.6) | 47 (41.2) | ||
| No | 31 (54.4) | 67 (58.8 | ||
| CD4 | 12.741 | <0.001 | ||
| <200 | 39 (68.4) | 45 (39.5) | ||
| >200 | 18 (31.6) | 69 (60.5 | ||
| Months ART has taken | 53.359 | <0.001 | ||
| <12 Months | 30 (52.6) | 8 (7.0) | ||
| 13–36 Months | 15 (26.3) | 25 (21.9) | ||
| >36 Months | 12 (21.1) | 8171.1) |
Abbreviations: ART, anti-retroviral treatment; BMI, body mass index; Hgb, hemoglobin; TB, tuberculosis; co-infection, infection with one or more infections other than TB; WHO, World Health Organization; IPT, isoniazid preventive treatment.